Exscientia CEO Andrew Hopkins at EUBIO22 (Rachel Kiki for Endpoints News)
Bristol Myers passes on two Exscientia oncology candidates, but biotech to move them into clinic next year
Exscientia said it expanded its pipeline Tuesday morning, but the biotech is doing so without the help of a yearslong partner …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
